When 78-year-old Margaret Thompson received her first dose of the Shingrix vaccine after a rehab stay at a Rhode Island skilled nursing facility, she wasn’t thinking about her long-term brain health—just preventing a painful shingles outbreak. But according to a new study led by Brown University, that single shot may have also quietly lowered her risk of developing dementia by 24% over the next four years. This isn’t just a story about one woman; it’s a pattern seen across more than half a million older Americans. Researchers analyzed Medicare claims and electronic health records from 509,926 adults aged 66 and older admitted to over 5,500 skilled nursing facilities between 2017 and 2022. Among them, only 8,843 received at least one dose of the recombinant zoster vaccine, known as Shingrix—the only shingles vaccine currently available in the U.S. Despite the low vaccination rate, the results were striking: just one dose was linked to a significantly lower chance of a dementia diagnosis.

The study, published in Annals of Internal Medicine and led by Kaley Hayes, assistant professor at Brown’s School of Public Health, stands out for its focus on a high-risk, under-vaccinated population. Unlike earlier research that looked at older vaccines, this one zeroes in on Shingrix, introduced in 2017, and uses a method called target trial emulation to approximate the rigor of a clinical trial. The findings add weight to a growing body of evidence suggesting that vaccines may do more than prevent infections—they might also protect the brain. Among vaccinated patients, 18.8% were diagnosed with dementia within four years, compared to 24.6% of unvaccinated peers. “This translates to about 1 in 17 dementia cases potentially being prevented,” Hayes said—an outcome as hopeful as it is measurable.

While the study can’t prove causation—vaccinated individuals were slightly younger and healthier—the team adjusted for these factors and still found a strong association. The implications are profound, especially in a country where dementia affects nearly 7 million people and rising. If future clinical trials confirm the link, a simple, already-approved vaccine could become a dual-purpose tool: shielding both skin and synapses. The research was partially funded by GlaxoSmithKline, the maker of Shingrix, though the company had no role in study design or publication decisions.

For Hayes, the takeaway is both scientific and deeply human. “Our cognition is so tied to our overall health and what happens to us physically,” she said. In an era where brain health feels increasingly fragile, the idea that a routine vaccine might help preserve memory, identity, and independence is not just promising—it’s a quiet revolution unfolding in nursing homes, clinics, and pharmacies across America.